Tagged Articles

canagliflozin 35 articles

Study finds Invokana effective despite side effects warnings

A researcher who works for Janssen Scientific Affairs, a division of Johnson & Johnson’s Janssen Pharmaceuticals, conducted a year-long study comparing the company’s type 2 diabetes drug Invokana with the diabetes drug glimepiride and determined that Invokana was better at improving glycemic control, blood pressure and weight loss than glimepiride in patients with type 2 diabetes. The study was presented last month at the AACE Annual Scientific and Clinical Congress. Invokana, known chemically as canagliflozin, is in a newer class of type 2 diabetes medications known as sodium-glucose cotransporter-2 (SGLT2) inhibitors. They lower blood sugary by causing the kidneys to ... Read More

NICE recommends diabetes drugs despite serious risks

The National Institute for Health and Care Excellence (NICE) is recommending the use of one of three drugs in a newer class of type 2 diabetes treatments if standard treatment is not suitable. The news comes on the heels of an announcement by the European drug regulator that it was conducting a safety review of one of the medications due to an increased risk of lower limb amputations and new warnings by the U.S. drug regulator for an increased risk of a serious condition called ketoacidosis. NICE is part of the UK’s Department of Health serving both the English National ... Read More

FDA: Invokana, Invokamet linked to foot, toe amputations

People who take the type 2 diabetes medication Invokana or Invokamet, both of which contain the active drug ingredient canagliflozin, are at an increased risk of foot amputations, mostly affecting the toes, the Food and Drug Administration (FDA) warned. The Safety Alert comes just weeks after the European Medicines Agency (EMA) announced that it was conducting an investigation into reports of lower limb amputations, specifically toe amputations, with the drug. The FDA said that results from an ongoing clinical trial found an increased risk of foot and toe amputations in patients treated with Invokana and Invokamet. The agency said it ... Read More

Invokana linked to numerous health problems in type 1 diabetic patient

A 41-year-old type 1 diabetic treated with Invokana suffered numerous health problems and did not improve until she was taken off the drug. Invokana, known chemically as canagliflozin, was approved in March of 2013 as a treatment for type 2 diabetes. It has been used off-label in some type 1 diabetics. Made by Johnson & Johnson’s Janssen Pharmaceuticals, Invokana is in a new class of diabetes medications known as SGLT2 inhibitors. The drugs help lower a patient’s high blood sugar by removing excess sugar through the kidneys and excreted in through the urine. Shortly after the drug was launched in ... Read More

Invokana plagued by new side effects since its FDA approval

It’s been three years since the Food and Drug Administration (FDA) approved Johnson & Johnson’s Janssen Pharmaceutical’s drug Invokana (canagliflozin) as a treatment for type 2 diabetes. Since then, the FDA and other drug regulators have issued numerous warnings over new Invokana side effects that have emerged outside initial clinical trials. Invokana was the first drug approved in the United States in a class known as sodium glucose cotransporter 2 (SGLT2) inhibitors. Prescriptions for the drug have since soared, generating hundreds of millions in revenue. In May 2015, the FDA issued a Safety Communication warning that Invokana and two other ... Read More

Invokana increases the risk of ketoacidosis in type 1 diabetics on insulin

Cases of ketoacidosis were reported in type 1 diabetic patients taking insulin in combination with the diabetes medication Invokana as early as 18 weeks after starting the drug, according to researchers with the American Diabetes Association. Invokana is approved to treat patients with type 2 diabetes, but the drug has been tested in patients with type 1 diabetes. Studies have already linked Invokana (known chemically as canagliflozin) and other type 2 diabetes drugs in the same class known as sodium glucose cotransporter 2 (SGLT2) inhibitors, with an increased risk of ketoacidosis. The new study aimed to evaluate whether the incidence ... Read More

Type 1 diabetics treated with Farxiga at risk for ketoacidosis

The type 2 diabetes drugs Farxiga and Victoza, when used together, are an effective treatment for managing blood sugar levels in patients with type 1 diabetes, but patients were at an increased risk of developing ketoacidosis, a serious condition in which too much acid builds up in the blood. The findings were noted by researchers with the State University of New York in Buffalo, who tested 30 patients already taking insulin and Victoza, known chemically as liraglutide, and randomly gave them either Farxiga, known chemically as dapagliflozin, or a placebo as an add-on for 12 weeks. HbA1c levels fell by ... Read More

Hypersensitivity warning added to Invokana, Invokamet

The Food and Drug Administration (FDA) has approved new safety label updates to the type 2 diabetes drugs Invokana (canagliflozin) and Invokamet (canagliflozin/metformin) to include warnings about the risk for serious hypersensitivity reactions including anaphylaxis and angioedema. Anaphylaxis is a serous, life-threatening whole-body allergic reaction. Symptoms include difficulty breathing, hives or swelling, tightness of the throat, hoarse voice, nausea, vomiting, fainting, low blood pressure, rapid heart beat, and cardiac arrest. Angioedema is a swelling of deep dermis, subcutaneous, or submucosal tissue due to vascular leakage. Acute episodes often involve the lips, eyes, and face, but it can also affect the ... Read More

Type 1 diabetics taking Invokana at greater risk for ketoacidosis

People with type 1 diabetes treated with Invokana (canagliflozin) are at an increased risk of developing ketoacidosis, a potentially life threatening acid buildup in the blood. If left untreated, ketoacidosis can lead to diabetic coma and death. Invokana is in a class of drugs known as SGLT2 inhibitors. The medication was approved by the Food and Drug Administration (FDA) in March 2013 for patients with type 2 diabetes. It is not approved for patients with type 1 diabetes. A study conducted by researchers with the University of Southern California and published in Diabetes Care tested Invokana on 234 patients with type ... Read More

Janssen awaits approval of extended release version of Invokamet

Johnson & Johnson’s Janssen Pharmaceuticals is awaiting FDA approval of an extended release version of its type 2 diabetes drug Invokamet, a combination of its Invokana and the long-used first-line diabetes treatment metformin. Patients prescribed Invokamet XR will take two tablets daily as an adjunctive treatment to diet and exercise for improved glycemic control for the treatment of type 2 diabetes. Invokana, which is known chemically as canagliflozin, was approved by the FDA in 2013, and was the first in a new class of diabetes treatments known as SGLT2 inhibitors. Invokamet was approved in 2014. Invokamet XR will be the ... Read More